Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Getinge ABSTU:GTN +0.68%76 Return-on-Tangible-Equity is Negative Tangible Equity% as of Jun. 2026. GuruFocus rates STU:GTN with a GF Score™ of 76/100 and a GF Value™ of €18.51 (Modestly Overvalued). The stock has 10 warning signs investors should review. Among 758 Medical Devices & Instruments companies, Getinge AB ranks better than 99.87% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Getinge AB's annualized net income for the quarter that ended in Jun. 2026 was €307 Mil. Getinge AB's average shareholder tangible equity for the quarter that ended in Jun. 2026 was €-381 Mil. Therefore, Getinge AB's annualized Return-on-Tangible-Equity for the quarter that ended in Jun. 2026 was Negative Tangible Equity%.
The historical rank and industry rank for Getinge AB's Return-on-Tangible-Equity or its related term are showing as below:
STU:GTN'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 137.32 Med: 164.26 Max: 191.2
Current: Negative Tangible Equity
During the past 13 years, Getinge AB's highest Return-on-Tangible-Equity was 191.20%. The lowest was 137.32%. And the median was 164.26%.
STU:GTN's Return-on-Tangible-Equity is ranked better than 99.87% of 758
companies
in the Medical Devices & Instruments industry
Industry Median: 4.08
vs STU:GTN: Negative Tangible Equity
Getinge AB (STU:GTN) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Getinge AB Return-on-Tangible-Equity Related Terms
Getinge AB Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Getinge AB's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:GTN vs ABT, SYK, MDT: Return-on-Tangible-Equity Comparison
For the Medical Devices subindustry, Getinge AB's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Getinge AB Return-on-Tangible-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Getinge AB's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Getinge AB's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Jun. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of Negative Tangible Equity% mean?
Getinge AB (STU:GTN) has a Return-on-Tangible-Equity of Negative Tangible Equity% as of Jun. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Getinge AB and its competitors. Over the past decade, Getinge AB's Return-on-Tangible-Equity has ranged from 137.32 to 191.20. According to the industry distribution chart, Getinge AB ranks #1 out of 758 companies in the Medical Devices & Instruments industry, placing it in the top 0.099999999999994%.
Is Getinge AB's Return-on-Tangible-Equity too high?
Getinge AB's current Return-on-Tangible-Equity is Negative Tangible Equity%. Over the past 10 years, this metric has ranged from a low of 137.32 to a high of 191.20. Based on the distribution chart, Getinge AB ranks #1 out of 758 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Getinge AB has a GF Score™ of 76/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Getinge AB's Return-on-Tangible-Equity compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Getinge AB ranks #1 out of 758 companies for Return-on-Tangible-Equity. This places Getinge AB in the top 0% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 4.08. Historically, Getinge AB's own Return-on-Tangible-Equity has ranged from 137.32 to 191.20 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Devices & Instruments company?
The median Return-on-Tangible-Equity among Medical Devices & Instruments companies is 4.08, based on 758 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Getinge AB and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Equity is 4.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Getinge AB's current Return-on-Tangible-Equity is Negative Tangible Equity%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Getinge AB stock overvalued right now?
Based on GuruFocus' analysis, Getinge AB (STU:GTN) is currently considered Modestly Overvalued. The stock's GF Value™ is €18.51, compared to a current price of €20.75 — trading 12.1% above its estimated fair value. The current Return-on-Tangible-Equity is Negative Tangible Equity%. Getinge AB's overall GF Score™ is 76/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Getinge AB (STU:GTN), the current Return-on-Tangible-Equity is Negative Tangible Equity% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Getinge AB (STU:GTN) Overvalued in 2026?
Based on GuruFocus' analysis, Getinge AB stock appears to be overvalued.
The current stock price of €20.75 is trading 12.1% above its estimated GF Value™ of €18.51.
GuruFocus considers Getinge AB to be Modestly Overvalued.
No single metric tells the full story. See the STU:GTN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Getinge, headquartered in Gothenburg, Sweden, manufactures a wide range of products for use in acute care, surgical, and life sciences in the hospital, pharmaceutical, and research settings. The company reports in three segments: acute care therapies (52% of revenue), surgical workflows (35%), and life sciences (13%). Product areas include ventilators, surgical stents, life support systems, sterilizers, surgical tables, and sterile transfer systems. Getinge derives revenue from a broad geographic footprint, with the Americas accounting for 45% of sales, Europe, Middle East, and Africa 35%, and Asia-Pacific the remaining 25%.
76GF Score
Get the complete analysis for STU:GTN
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:GTN has been successfully added to your 
